{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:05:30Z","timestamp":1781085930659,"version":"3.54.1"},"reference-count":45,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hypersensitivity reactions (HSR) are reported for the macrolides, lincosamides, and streptogramins (MLS) antibiotic family. Data about cross\u2010reactivity among and between MLS remain scarce or controversial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to provide an overview of hypersensitivity cross\u2010reactions among MLSs based on data extracted from the French National Pharmacovigilance Database (FPVD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases of HSR to MLSs reported between January 1985 and December 2019 were extracted from the FPVD using standardized MedDRA queries (SMQ). Cases including an allergological test involving multiple MLSs and giving at least one positive result were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 8394 cases reviewed, 149 were included. HSR mainly involved pristinamycin (<jats:italic>n<\/jats:italic>\u00a0=\u200983; 53.2%) and spiramycin (<jats:italic>n<\/jats:italic>\u00a0=\u200931; 19.9%). HSR to MLS was immediate in 54 cases and delayed in 94 cases. Skin tests represented the majority of the allergological tests performed (<jats:italic>n<\/jats:italic>\u00a0=\u2009728; 84.7%), followed by reintroduction tests (<jats:italic>n<\/jats:italic>\u00a0=\u200979; 9.2%). Eighty\u2010six cross\u2010reactivities among MLS were identified in 62 cases (41.6%). All the 25 explorations performed for streptogramins showed cross\u2010reactivities, but only 30\/253 among macrolides (11.9%). Cross\u2010reactivities between the three MLS were observed in 31\/322 (9.6%) of the allergological explorations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study highlights the possibility of cross\u2010reactivity among and between MLSs. Dermatologists and allergologists managing patients with HSR to MLSs should be aware of a risk of cross\u2010reactivity among the macrolides and between the different classes of MLS and to perform MLSs allergological testing before recommending an alternative antibiotic, especially in severe drug hypersensitivity from the MLS family.<\/jats:p><\/jats:sec>","DOI":"10.1111\/fcp.13005","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:45:56Z","timestamp":1712637956000},"page":"988-997","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cross\u2010reactivity among and between macrolides, lincosamides, and streptogramins: Study on the French pharmacovigilance database"],"prefix":"10.1111","volume":"38","author":[{"given":"Quentin","family":"Le Baron","sequence":"first","affiliation":[{"name":"Department of Pharmacology\u2010Toxicology and Pharmacovigilance University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-7558","authenticated-orcid":false,"given":"Delphine","family":"Bourneau\u2010Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2010Toxicology and Pharmacovigilance University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2010Toxicology and Pharmacovigilance University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Gouraud","sequence":"additional","affiliation":[{"name":"CRPV, CHU Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[{"name":"Department of Allergology and Clinical Immunology Inserm 1111 CIRI, CHU Lyon  Lyon France"},{"name":"French Investigators for Skin Adverse Reactions to Drugs (FISARD) group from the French Society of Dermatology  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-9846","authenticated-orcid":false,"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[{"name":"CRPV, CHRU Nancy  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun\u2010Vignes","sequence":"additional","affiliation":[{"name":"French Investigators for Skin Adverse Reactions to Drugs (FISARD) group from the French Society of Dermatology  Paris France"},{"name":"CRPV Paris Piti\u00e9\u2010St Antoine, APHP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Delaunay","sequence":"additional","affiliation":[{"name":"French Investigators for Skin Adverse Reactions to Drugs (FISARD) group from the French Society of Dermatology  Paris France"},{"name":"Department of Dermatology University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Morisset","sequence":"additional","affiliation":[{"name":"Department of Pneumology University Hospital of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-5998","authenticated-orcid":false,"given":"Marie","family":"Briet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2010Toxicology and Pharmacovigilance University Hospital of Angers  Angers France"},{"name":"Univ Angers, Inserm, CNRS, MITOVASC, Equipe CarMe, SFR ICAT  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"European Surveillance of Antimicrobial Consumption Network (ESAC\u2010Net)","author":"European Centre for Disease Prevention and Control [Internet]"},{"issue":"478","key":"e_1_2_13_3_1","first-page":"51","article-title":"Les macrolides et apparent\u00e9s","volume":"47","author":"Faure S","year":"2008","journal-title":"Actual Pharm"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161208786369812"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08878-x"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.010"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1939-4551-6-18"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700116"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017907"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.5152\/TurkArchPediatr.2022.21223"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.06.036"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000323"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16738"},{"key":"e_1_2_13_14_1","volume-title":"Pharmacovigilance: Overview","author":"EMA. European Medicines Agency","year":"2018"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.029"},{"key":"e_1_2_13_16_1","volume-title":"ICH Official Web Site: ICH [Internet]"},{"key":"e_1_2_13_17_1","volume-title":"English | MedDRA [Internet]"},{"key":"e_1_2_13_18_1","volume-title":"Standardised MedDRA Queries | MedDRA [Internet]"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12350"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2003.00279.x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12429"},{"key":"e_1_2_13_22_1","volume-title":"Bonnes pratiques de pharmacovigilance \u2010 2018 [Internet]"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.5414\/ALX02422E"},{"key":"e_1_2_13_24_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 ZITHROMAX 250 mg, comprim\u00e9 pellicul\u00e9 \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_25_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 ZECLAR 250 mg, comprim\u00e9 pellicul\u00e9 \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_26_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 RULID 150 mg, comprim\u00e9 enrob\u00e9 \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_27_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 ROVAMYCINE 1,5 MILLIONS D'UNITES INTERNATIONALES, lyophilisat pour usage parent\u00e9ral \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_28_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 PYOSTACINE 500 mg, comprim\u00e9 pellicul\u00e9 \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_29_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 JOSACINE 1000 mg, comprim\u00e9 dispersible \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_30_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 ERYTHROMYCINE PANPHARMA 1 g, poudre pour solution \u00e0 diluer pour perfusion \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_31_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2010 DALACINE 600 mg, solution injectable \u2010 Base de donn\u00e9es publique des m\u00e9dicaments [Internet]"},{"key":"e_1_2_13_32_1","volume-title":"R\u00e9sum\u00e9 des caract\u00e9risitques du produit \u2010 KETEK 400mg [Internet]"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40521\u2010017\u20100128\u20102"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00638.x"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2010.06.008"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13084"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08156.x"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.016"},{"issue":"3","key":"e_1_2_13_39_1","first-page":"E135","article-title":"Macrolide allergic reactions","volume":"7","author":"Shaeer KM","year":"2019","journal-title":"Pharm Basel Switz"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_C.1"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.08.009"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283630c36"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2012.03.017"},{"key":"e_1_2_13_44_1","volume-title":"Article R5121\u2010161 \u2010 Code de la sant\u00e9 publique \u2010 L\u00e9gifrance [Internet]"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.13.1588"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02120.x"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.13005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T10:12:10Z","timestamp":1732097530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.13005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/fcp.13005"],"URL":"https:\/\/doi.org\/10.1111\/fcp.13005","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"2023-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}